Invent Medic Sweden AB (XSAT:IMS) ROE %: -55.59% (As of Mar. 2026)


XSAT:IMS Invent Medic Sweden AB XSAT:IMS
38 GF Score
Price kr0.13
GF Value kr0.18
Valuation Modestly Undervalued
! 2 Warning Signs
View Full Analysis

What is Invent Medic Sweden AB ROE %?

Invent Medic Sweden AB XSAT:IMS -3.73% 38 ROE % is -55.59% as of Mar. 2026. GuruFocus rates XSAT:IMS with a GF Score™ of 38/100 and a GF Value™ of kr0.18 (Modestly Undervalued). The stock has 2 warning signs investors should review. Among 799 Medical Devices & Instruments companies, Invent Medic Sweden AB ranks worse than 86.61% on this metric.

ROE % is calculated as Net Income divided by its average Total Stockholders Equity over a certain period of time. Invent Medic Sweden AB's annualized net income for the quarter that ended in Mar. 2026 was kr-3.32 Mil. Invent Medic Sweden AB's average Total Stockholders Equity over the quarter that ended in Mar. 2026 was kr5.98 Mil. Therefore, Invent Medic Sweden AB's annualized ROE % for the quarter that ended in Mar. 2026 was -55.59%.

The historical rank and industry rank for Invent Medic Sweden AB's ROE % or its related term are showing as below:

XSAT:IMS' s ROE % Range Over the Past 10 Years
Min: -198.48   Med: -117.57   Max: -60.76
Current: -72.82

During the past 10 years, Invent Medic Sweden AB's highest ROE % was -60.76%. The lowest was -198.48%. And the median was -117.57%.

XSAT:IMS's ROE % is ranked worse than
86.61% of 799 companies
in the Medical Devices & Instruments industry
Industry Median: 2.42 vs XSAT:IMS: -72.82

Invent Medic Sweden AB  (XSAT:IMS) ROE % Explanation

ROE % measures the rate of return on the ownership interest (shareholder's equity) of the common stock owners. It measures a firm's efficiency at generating profits from every unit of shareholders' equity (also known as net assets or assets minus liabilities). ROE % shows how well a company uses investment funds to generate earnings growth. ROE %s between 15% and 20% are considered desirable.

The factors that affect a company's ROE % can be illustrated with the three-step DuPont Analysis:

ROE %(Q: Mar. 2026 )
=Net Income/Total Stockholders Equity
=-3.324/5.979
=(Net Income / Revenue )*(Revenue / Total Assets)*(Total Assets / Total Stockholders Equity)
=(-3.324 / 8.236)*(8.236 / 9.5985)*(9.5985 / 5.979)
=Net Margin %*Asset Turnover*Equity Multiplier
=-40.36 %*0.8581*1.6054
=ROA %*Equity Multiplier
=-34.63 %*1.6054
=-55.59 %

With this breakdown, it is clear that if a company grows its Net Profit Margin, its Asset Turnover, or its Leverage, it can grow its ROE %.

The factors that affect a company's ROE % can also be illustrated with the five-step DuPont Analysis:

ROE %(Q: Mar. 2026 )
=Net Income/Total Stockholders Equity
=-3.324/5.979
=(Net Income / Pre-Tax Income) * (Pre-Tax Income / Operating Income) * (Operating Income / Revenue) * (Revenue / Total Assets) * (Total Assets / Total Stockholders Equity)
= (-3.324 / -3.324) * (-3.324 / -3.108) * (-3.108 / 8.236) * (8.236 / 9.5985) * (9.5985 / 5.979)
= Tax Burden * Interest Burden * Operating Margin % * Asset Turnover * Equity Multiplier
= 1 * 1.0695 * -37.74 % * 0.8581 * 1.6054
=-55.59 %

Note: The net income data used here is four times the quarterly (Mar. 2026) net income data. The Revenue data used here is four times the quarterly (Mar. 2026) revenue data. The same rule applies to Pre-Tax Income and Operating Income.
* In the five-step DuPont Analysis, Operating Income is only available for non-financial companies. Thus, for Insurance companies, we use EBIT as a substitution of Operating Income. For Banks, both Operating Income and EBIT is unavailable. Thus we combined Interest Burden and Operating Margin % into Pretax Margin %, and the DuPont Analysis is divided into four components instead.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Be Aware

Net Income is used.

Because a company can increase its ROE % by having more financial leverage, it is important to watch the equity multiplier when investing in high ROE % companies. Like ROA %, ROE % is calculated with only 12 months data. Fluctuations in company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.

Asset light businesses require very few assets to generate very high earnings. Their ROE %s can be extremely high.


Invent Medic Sweden AB ROE % Related Terms


Invent Medic Sweden AB ROE % Historical Data

* Premium members only.

The historical data trend for Invent Medic Sweden AB's ROE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Invent Medic Sweden AB ROE % Chart

Invent Medic Sweden AB Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
ROE %
Get a 7-Day Free Trial Premium Member Only Premium Member Only -129.39 -105.32 -162.07 -161.84 -107.35

Invent Medic Sweden AB Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
ROE % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -111.87 -92.20 -64.99 -75.01 -55.59

XSAT:IMS vs ABT, SYK, MDT: ROE % Comparison

For the Medical Devices subindustry, Invent Medic Sweden AB's ROE %, along with its competitors' market caps and ROE % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Invent Medic Sweden AB ROE % vs Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Invent Medic Sweden AB's ROE % distribution charts can be found below:

* The bar in red indicates where Invent Medic Sweden AB's ROE % falls into.


XSAT:IMS
38GF Score
Invent Medic Sweden AB XSAT:IMS
ROE % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Invent Medic Sweden AB ROE % Calculation

Invent Medic Sweden AB's annualized ROE % for the fiscal year that ended in Dec. 2025 is calculated as

ROE %=Net Income (A: Dec. 2025 )/( (Total Stockholders Equity (A: Dec. 2024 )+Total Stockholders Equity (A: Dec. 2025 ))/ count )
=-5.201/( (4.311+5.379)/ 2 )
=-5.201/4.845
=-107.35 %

Invent Medic Sweden AB's annualized ROE % for the quarter that ended in Mar. 2026 is calculated as

ROE %=Net Income (Q: Mar. 2026 )/( (Total Stockholders Equity (Q: Dec. 2025 )+Total Stockholders Equity (Q: Mar. 2026 ))/ count )
=-3.324/( (5.379+6.579)/ 2 )
=-3.324/5.979
=-55.59 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual ROE %, the net income of the last fiscal year and the average total shareholder equity over the fiscal year are used. In calculating the quarterly data, the net income data used here is four times the quarterly (Mar. 2026) net income data. ROE % is displayed in the 30-year financial page.

Frequently Asked Questions Learn more about ROE % →
What does a ROE % of -55.59% mean?
Invent Medic Sweden AB (XSAT:IMS) has a ROE % of -55.59% as of Mar. 2026. Return on equity is the ratio of current-period net income to average two-period total equity. View historical data on Invent Medic Sweden AB and its competitors. According to the industry distribution chart, Invent Medic Sweden AB ranks #692 out of 799 companies in the Medical Devices & Instruments industry, placing it in the top 86.6%.
Is Invent Medic Sweden AB's ROE % too high?
Invent Medic Sweden AB's current ROE % is -55.59%. Based on the distribution chart, Invent Medic Sweden AB ranks #692 out of 799 companies in the Medical Devices & Instruments industry, which is in the bottom quartile relative to peers. Overall, Invent Medic Sweden AB has a GF Score™ of 38/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Invent Medic Sweden AB's ROE % compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, Invent Medic Sweden AB ranks #692 out of 799 companies for ROE %. This places Invent Medic Sweden AB in the lower half of its industry. The industry median ROE % is 2.42. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROE % for a Medical Devices & Instruments company?
The median ROE % among Medical Devices & Instruments companies is 2.42, based on 799 companies in the industry. Companies in the top quartile (top 25%) have a ROE % significantly above this median, while those in the bottom quartile fall well below. However, ROE % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROE % mean?
A high ROE % can signal that a stock is expensive relative to its fundamentals. Return on equity is the ratio of current-period net income to average two-period total equity. View historical data on Invent Medic Sweden AB and its competitors. For the Medical Devices & Instruments industry, the median ROE % is 2.42 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Invent Medic Sweden AB's current ROE % is -55.59%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Invent Medic Sweden AB stock overvalued right now?
Based on GuruFocus' analysis, Invent Medic Sweden AB (XSAT:IMS) is currently considered Modestly Undervalued. The stock's GF Value™ is kr0.18, compared to a current price of kr0.13 — trading 28.3% below its estimated fair value. The current ROE % is -55.59%. Invent Medic Sweden AB's overall GF Score™ is 38/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROE % calculated?
ROE % is calculated from a company's financial statements. For Invent Medic Sweden AB (XSAT:IMS), the current ROE % is -55.59% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Invent Medic Sweden AB (XSAT:IMS) Overvalued in 2026?

Based on GuruFocus' analysis, Invent Medic Sweden AB stock appears to be undervalued. The current stock price of kr0.13 is trading 28.3% below its estimated GF Value™ of kr0.18. GuruFocus considers Invent Medic Sweden AB to be Modestly Undervalued.

Key valuation signals for XSAT:IMS:

  • ROE %: -55.59%
  • GF Value™: kr0.18 vs. price of kr0.13 (28.3% below fair value)
  • GF Score™: 38/100 with 2 warning signs

No single metric tells the full story. See the XSAT:IMS stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Invent Medic Sweden AB Business Description

Address Nytenkargatan 4, Lund, SWE, 223 63
Invent Medic Sweden AB develops and markets its product - Efemia bladder support, a vaginal medical device for the treatment of female urinary incontinence.
38GF Score

Get the complete analysis for XSAT:IMS

ROE % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

kr0.13
Price
kr0.18
GF Value